Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.
Quick Facts
Reference Sizes
1 mg
Storage
Per FDA label: storage varies by formulation - verify current label before recording.
Solubility
Lyophilized injection product is reconstituted only with its supplied diluent
Best-Effort Research Profile
Glucagon is a pancreatic alpha-cell hormone that raises blood glucose via hepatic glycogenolysis and gluconeogenesis, functioning in opposition to insulin. It is FDA-approved (multiple formulations, including nasal and auto-injector rescue products) for emergency treatment of severe hypoglycemia. In modern incretin-pharmacology research, controlled glucagon receptor co-agonism (alongside GLP-1 and/or GIP) is deliberately incorporated into triple agonists like retatrutide to add an energy-expenditure component to appetite-suppression/insulin-sensitizing effects - a research design distinct from glucagon's classical emergency-hypoglycemia use.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Research Profile
Half-Life
Product and route dependent; approximately 42 minutes after SC and 26 minutes after IM administration in the cited label
Onset
Maximum glucose response after SC dosing occurs at about 50 minutes; GI smooth-muscle relaxation begins within seconds to minutes depending on route
Raises blood glucose via hepatic glycogenolysis/gluconeogenesis (approved emergency use)
Glucagon receptor co-agonism contributes an energy-expenditure component in modern triple-agonist research (e.g., retatrutide)
Reported Research Side Effects
Nausea
Vomiting
Headache
Injection-site reaction
Hypersensitivity
Transient tachycardia or blood-pressure increase
Data source: Current U.S. prescribing information
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Route-Specific Research Protocols
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
Label / guidelineHuman studyCommunity onlyPreclinical onlyNot established
Subcutaneous (SC)Label / guideline
1 mg as a single emergency dose for severe hypoglycemia in patients at least 20 kg
Frequency / timing
Once
Duration / setting
Emergency single dose
Technique
SC IM
Evidence
Regulatory label
Context: current DailyMed injection label
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.
1 mg as a single emergency dose for severe hypoglycemia in patients at least 20 kg
Frequency / timing
Once
Duration / setting
Emergency single dose
Technique
IV
Evidence
Regulatory label
Context: current DailyMed injection label
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: Use only in the cited label or guideline context; route, formulation, indication, and patient-specific limits still apply.
No route-specific amount established in the reviewed record.
Technique
IM
Evidence
Route noted; protocol not established
Context: The catalog identifies this route, but its reviewed sources do not establish a separate amount and schedule for it.
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: No route-specific protocol is established. Do not infer an amount from another route, component, or formulation.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Research Interactions
Flagged Avoid / Caution Combinations (Research)
Pheochromocytoma
Insulinoma
Known hypersensitivity
Glucagonoma when used as a diagnostic aid
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
Research Notes
Glucagon is an approved emergency medicine, not merely a research peptide. Nasal and ready-to-use analog products have product-specific instructions and are not interchangeable with a 1 mg vial.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Related Research Articles
Published articles on this site that mention Glucagon or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.